Attend the FierceBiotech 3rd Drug Development Forum!
The leading executive-level forum for biotech strategy & networking | Oct 1-3 | Boston
Novartis will take MOR106 forward in atopic dermatitis and other indications, handing over up to €850 million in milestones as it goes.
The deal sees Kite take a stake in Gadeta and commit to milestones tied to the progress of oncology candidates.
IFM Therapeutics is hiving off its NLRP3 stable into a subsidiary dubbed IFM Tre, which expects to advance its lead asset into phase 1 next year.
A startup from Johns Hopkins launched with $36 million to bring a potentially disease-modifying drug into phase 1 for Parkinson’s disease.
The pair will start three new trials in the third quarter, including a phase 2 pilot study in CDKL5 deficiency disorder and duplication 15q syndrome.
A new “venture philanthropy” accelerator is offering over $30 million in grants for new biomarkers and diagnostic tests for Alzheimer’s disease.
Pfizer and Eli Lilly’s NGF inhibitor tanezumab is closer to becoming an alternative to opioid analgesics for pain after a positive phase 3 trial.
The partners plan to move small molecule SHP2 inhibitor RMC-4630 into the clinic later this year.
The voted-for text tasks the government with seeking to secure the right for the U.K. to “fully participate” in the EMA after Brexit.
Roivant is debuting another "vant," dubbed Sinovant, whose mission is to "bring innovative medicines" to—you guessed it—China.